Connecticut hasn’t received an official warning yet on food stamp funding. Governor Hochul wants changes made to an aid in dying bill before signing it. Plus, parents of children with autism in ...

It didn't look like Alabama basketball and Nate Oats would meet Buzz Williams again for some time after the coach left Texas A&M for Maryland. Alas, the Crimson Tide faced the three-piece wonder − who ...

LOUISVILLE, KY — Clemson football is one win away from being bowl eligible. Clemson upset No. 21 Louisville on the road, winning 20-19 on Friday at L&N Federal Credit Union Stadium. Louisville backup ...

The San Francisco 49ers’ injury report was most of the core of their NFC championship team from a couple seasons ago. They had to play extremely short-handed while going on the road on short rest ...

As SQL development increasingly becomes part of full-stack workflows, developers are looking for ways to simplify their tooling without compromising capability. While SQL Server Management Studio ...

The graph database market, driven by AI, is growing at a rate of almost 25% annually. Graph databases support knowledge graphs, providing visual guidance for AI development. There are multiple ...

Washington, D.C. is not a war zone, but you wouldn’t know it from the president’s orders. The real crisis is that Trump is ignoring research-backed crime deterrent strategies and actively gutting ...

MongoDB MDB and Oracle ORCL are two leading names in the database market, but they’re built on very different foundations. MongoDB is a developer-first, cloud-native NoSQL platform optimized for ...

Forbes contributors publish independent expert analyses and insights. I write about the economics of AI. When Snowflake announced its $250 million acquisition of Crunchy Data two weeks ago at its ...

GitHub Copilot continues to evolve in both Visual Studio and Visual Studio Code, offering developers increasingly intelligent, context-aware tools that go far beyond basic autocomplete. The latest ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in the company's partner Summit ...